In a recent paper in the British Journal of Pharmacology the group of professor Di Marzo showed that exogenous PEA can be of use in Irritable bowel syndrome (IBS). In an elegant model PEA could normalize pathology related to intestinal motility. Their experiments are also relevant as they for the first time proved that formulation of PEA are not an issue al all; PEA in the expensive patented ultramicronized form has exactly the same dose-range as pure PEA. This was already be suspected in recent papers on PEA, and especially brought forward by Kriek. In a previous paper pure PEA in a colitis model could do the same, if not more.
Sigs of inferiority of ultramicronized PEA?
Moreover, The results of the study suggests inferiority of the special Epitech formulation related to normal PEA. Normal PEA is active in models like these, and in nearly all other pharmacological models in a dose range between 2.5-50 mg/kg BW, and mostly 5 and 10 mg/kg are tested. In the ultramicronized PEA no dose range could be found per os, only 5 mg/kg BW worked a little. It might be that the ultra fine particles are easily destroyed in the intestinal gut, while the normal PEA does not.
Capasso R, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F, Di Marzo V, Izzo AA. Ultramicronized palmitoylethanolamide normalizes intestinal motility in a murine model of post-inflammatory accelerated transit: involvement of CB1/sub receptors and TRPV1. Br J Pharmacol. 2014 May 12. doi: 10.1111/bph.12759.
Kriek R. Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives. Inflammopharmacology. 2014 Mar 20. PMID: 24647619
Kriek R. Marketing messages in pharmacological papers and scientific chapters: The case of palmitoylethanolamide and its formulations. Pharmacol Res. 2014 Apr 24. pii: S1043-6618(14)00047-4. doi: 10.1016/j.phrs.2014.04.007.